U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13NO2
Molecular Weight 167.205
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLEPHRINE

SMILES

CNC[C@H](O)C1=CC=CC(O)=C1

InChI

InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

HIDE SMILES / InChI
Molecular Formula C9H13NO2
Molecular Weight 167.205
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Berefrine (also known as phenylephrine oxazolidine), a prodrug of phenylephrine, is a mydriatic agent. Berefrine was developed for improving ocular absorption and reducing systemic side effects.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Phenylephrine does not cross the blood–brain barrier

Originator

Approval Year

1934
12
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 55.0 nM [EC50]
Agonist
2752
 5.9 nM [EC50]
Agonist
2752
 154.88 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
VAZCULEP

Approved Use

VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Launch Date

1953
Diagnostic
Approved
8583
Phenylephrine Hydrochloride Ophthalmic Solution

Approved Use

Indicated to dilate the pupil

Launch Date

1938
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1354 pg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2959 pg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4492 pg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
955.8 pg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2346 pg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 pg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.89 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.93 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.64 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26267590
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33062792
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/33062792
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (acute)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33062792
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Disc. AE: Chest pain, Jaw pain...
Other AEs: Nervous system disorders, Headache...
AEs leading to
discontinuation/dose reduction:
Chest pain (1 patient)
Jaw pain (1 patient)
Other AEs:
Nervous system disorders (3.6%)
Headache (2.7%)
Gastrointestinal disorders (8%)
Dry mouth (2.7%)
Nausea (3.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Other AEs: Eye pain, Blurred vision...
Other AEs:
Eye pain
Blurred vision
Photophobia
Allergic conjunctivitis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
250 ug single, intravenous
Recommended
Dose: 250 ug
Route: intravenous
Route: single
Dose: 250 ug
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis acute
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33062792
unhealthy, 34 years
Health Status: unhealthy
Age Group: 34 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/33062792
Chest pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Jaw pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Dry mouth 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Headache 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Nausea 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Nervous system disorders 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Gastrointestinal disorders 8%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
Health Status: unhealthy
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/26143019
Allergic conjunctivitis
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Blurred vision
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Eye pain
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Photophobia
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
832
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 yes
PubMed

PubMed

TitleDatePubMed
Contribution of ryanodine receptor subtype 3 to ca2+ responses in Ca2+-overloaded cultured rat portal vein myocytes.
2001-04-06
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001-03
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.
2001-03
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.
2001-03
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.
2001-03
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.
2001-03
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.
2001-03
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats.
2001-03
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001-02-16
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin.
2001-02-13
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.
2001-02-07
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.
2001-02-01
Influence of a multideficient diet from northeastern Brazil on resting blood pressure and baroreflex sensitivity in conscious, freely moving rats.
2001-02
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.
2001-02
Reflex cardiovascular responses originating in exercising muscles of mice.
2001-02
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility.
2001-02
Nitric oxide-mediated arteriolar dilation after endothelial deformation.
2001-02
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control.
2001-02
Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1.
2001-02
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.
2001-02
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.
2001-01-19
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.
2001-01-19
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.
2001-01-15
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001-01-12
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.
2001-01-05
Insulin-induced relaxation of rat mesenteric artery is mediated by Ca(2+)-activated K(+) channels.
2001-01-05
Dietary restriction in pregnant rats causes gender-related hypertension and vascular dysfunction in offspring.
2001-01-01
Methylene blue as a successful treatment alternative for pharmacologically induced priapism.
2001-01
Detection and characterization of cholinergic oscillatory control in the forehead microvasculature in response to systemic alpha-agonist infusion in healthy volunteers.
2001-01
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.
2001-01
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP.
2001-01
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats.
2001-01
Effects of LY117018 and the estrogen analogue, 17alpha-ethinylestradiol, on vascular reactivity, platelet aggregation, and lipid metabolism in the insulin-resistant JCR:LA-cp male rat: role of nitric oxide.
2001-01
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.
2001-01
Increased dilator response to heptanol and octanol in aorta from DOCA-salt-hypertensive rats.
2001-01
In vivo measurement of pulsewave velocity in small vessels using intravascular MR.
2001-01
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature.
2001-01
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.
2001-01
Should the angiotensin II antagonists be discontinued before surgery?
2001-01
Effects of acute and chronic hypertension on the labyrinthine barriers in rat.
2001-01
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.
2001-01
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats.
2001-01
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.
2001-01
Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release.
2001-01
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.
2001-01
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats.
2001-01
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.
2001-01
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction.
2001-01
Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow.
2001-01
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.
2000-12-31
Patents

Patents

JP2002212067A
6
JP2005520797A
9
JP2010241834A
10
JP3553083B2
51
JP4246265B2
9
JP5362549B2
6
JPS6333327A
6

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.
Route of Administration: Intravenous
In Vitro Use Guide
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:46:45 GMT 2025
Edited
by admin
on Mon Mar 31 17:46:45 GMT 2025
Record UNII
1WS297W6MV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYLEPHRINE MINIMS
Preferred Name English
PHENYLEPHRINE
EP   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
J8.601K
Code English
M-SYMPATHOL
Common Name English
M-SYNEPHRINE
Common Name English
AB-101 (PHENYLEPHRINE)
Code English
(R)-PHENYLEPHRINE
Common Name English
(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL
Systematic Name English
PHENYLEPHRINE, (R)-
Common Name English
R(-)-MEZATON
Common Name English
PHENYLEPHRINE [HSDB]
Common Name English
(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL
Systematic Name English
M-OXEDRINE
Common Name English
Phenylephrine [WHO-DD]
Common Name English
PHENYLEPHRINE [VANDF]
Common Name English
PHENYLEPHRINE [MI]
Common Name English
META-SYNEPHRINE
Common Name English
phenylephrine [INN]
Common Name English
M-SYMPATOL
Common Name English
PHENYLEPHRINE [EP IMPURITY]
Common Name English
PHENYLEPHRINE [EP MONOGRAPH]
Common Name English
METASYNEPHRINE
Common Name English
(-)-PHENYLEPHRINE
Common Name English
PHENYLEPHRINE [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 773
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QR01BA03
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QS01FB01
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QR01AA04
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QC01CA06
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC R01BA03
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC R01AB01
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC R01BA53
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QS01GA55
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC C01CA06
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC S01BB01
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QS01GA05
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-VATC QR01AB01
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC S01FB51
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
WHO-ATC S01FB01
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
FDA ORPHAN DRUG 147201
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
WHO-VATC QR01BA53
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
NCI_THESAURUS C29709
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
WHO-ATC S01GA55
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
NDF-RT N0000186105
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC R01AA04
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
WHO-ATC S01GA05
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
FDA ORPHAN DRUG 359011
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C62067
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
CAS
59-42-7
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
RXCUI
8163
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
MESH
D010656
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
ChEMBL
CHEMBL1215
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
RXCUI
325517
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
ALTERNATIVE
DAILYMED
1WS297W6MV
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
CHEBI
8093
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023465
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
IUPHAR
485
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
EVMPD
SUB09788MIG
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
HSDB
3383
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
DRUG BANK
DB00388
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
LACTMED
Phenylephrine
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
PUBCHEM
6041
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-424-8
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
DRUG CENTRAL
2146
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
NDF-RT
N0000009917
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY Adrenergic alpha1-Agonists [MoA]
FDA UNII
1WS297W6MV
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
MERCK INDEX
m8668
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY Merck Index
SMS_ID
100000088260
Created by admin on Mon Mar 31 17:46:46 GMT 2025 , Edited by admin on Mon Mar 31 17:46:46 GMT 2025
PRIMARY
WIKIPEDIA
PHENYLEPHRINE
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
INN
4174
Created by admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
PRIMARY
Related Record Type Details
Structure of PHENYLEPHRINE TANNATE
SALT/SOLVATE -> PARENT
Structure of PHENYLEPHRINE BITARTRATE
SALT/SOLVATE -> PARENT
ALPHA-1B ADRENERGIC RECEPTOR
TARGET -> AGONIST
Binding Assay
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of PHENYLEPHRINE PALMITATE
SALT/SOLVATE -> PARENT
Structure of PHENYLEPHRINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of PHENYLEPHRINE, (±)-
RACEMATE -> ENANTIOMER
Structure of PHENYLEPHRINE SULFATHIAZOLE
SALT/SOLVATE -> PARENT
ALPHA-1A ADRENERGIC RECEPTOR
TARGET -> AGONIST
Structure of PHENYLEPHRINE CYCLOHEXYLSULFAMATE
SALT/SOLVATE -> PARENT
Structure of PHENYLEPHRINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BEREFRINE
PRODRUG -> METABOLITE ACTIVE
Structure of PHENYLEPHRINE GLUCURONIDE
METABOLITE -> PARENT
Related Record Type Details
Structure of PHENYLEPHRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENZYLPHENYLEPHRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORFENEFRINE, (R)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-nitroso-phenylephrine
IMPURITY -> PARENT
Structure of BENZYLPHENYLEPHRINE
IMPURITY -> PARENT
EP
Related Record Type Details
Structure of PHENYLEPHRINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Vdss PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966